ABSORBABLE STERILE SURGICAL SUTURES

Information

TRUSYNTH - POLYGLACTIN 910 SUTURE TRUSYNTH FAST - POLYGLACTIN 910 FAST SUTURE TRUGYLDE - POLYGLYCOLIC ACID SUTURE TRUGYLDE FAST - POLYGLYCOLIC ACID FAST SUTURE PD SYNTH - POLYDIOXANONE SUTURE TRUBARB - POLYDIOXANONE KNOT LESS TISSUE - CLOSER DEVICE MONOGLYDE - POLIGLECAPRONE 25 SUTURE TRUGUT PLAIN - CATGUT PLAIN TRUGUT CHROMIC - CATGUT CHROMIC
Visit ID (prod)
2dm0eux7nsnln
HEALTHIUM MEDTECH LTDH3.J50Healthium Medtech Limited is a global medtech company focused on products used in surgical, post-surgical and chronic care. One in five surgeries conducted globally uses a Healthium Medtech product as of 31st March,2021. As of fiscal 2021, it is India’s largest independent medical device company and second-largest company overall, in the surgical consumables market. In the non-captive surgical needles segment, Healthium Medtech is the largest manufacturer globally, by volume as of March 31, 2021. Healthium Medtech is the third-largest company overall in urology collection devices market in the U.K as of fiscal 2021. With a vision to provide access to precision medtech for every patient, globally, the Company has created extensive market access in India covering over 40,000 surgeons across 18,000 hospitals, reaching 90% of all districts in India, which have secondary healthcare facilities. It also is present across 80 countries.The Company’s diverse portfolio includes 52,000 SKUs across Advanced surgery, Urology, Arthroscopy and wound care products. With a strong focus on R & D, the company has 8 high precision, integrated and scaled manufacturing facilities with global certifications and approvals like US FDA, C.E, CDSCO, TGA and ISO. Since fiscal 2018, the company has sold 30 new products including a patented portfolio of arthroscopy products. As on July 31, 2021, the Company had a total of 21 patents in India and 11 patents in United States, and a further 22 and 6 patent applications pending approval in India and US, respectively. In addition, it has acquired 3 businesses in the last few months to expand market reach and its product portfolio.